Pituitary adenomas in childhood

Indian Journal of Pediatrics

Volumn 72, Issue 7, 2005, Pages 583-591

  Singh, S K ^a   Aggarwal, Rohit ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Adolescence; Hypopituitarism; Pituitary adenoma

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; MITOTANE; OCTREOTIDE; QUINAGOLIDE; SOMATOSTATIN DERIVATIVE;

ADOLESCENCE; AMENORRHEA AND OLIGOMENORRHEA; CANCER CLASSIFICATION; CANCER SURGERY; CHILDHOOD CANCER; CLINICAL FEATURE; DRUG HALF LIFE; GALACTORRHEA; GENE MUTATION; GROWTH RETARDATION; HEADACHE; HUMAN; HYPOPHYSIS ADENOMA; HYPOPITUITARISM; HYPOTHALAMUS; PATHOGENESIS; PUBERTY; QUALITY OF LIFE; REVIEW;

EID: 23844478238     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02724183     Document Type: Review

References (46)

1. Odom GL, Davis CH, Woodhall B. Brain tumors in children. Clinical analysis in 164 cases. Pediatrics 1956;18:856-869.
2. Colao A, Boche S, Cappabianca P, de Divitiis E, Lombardi G. Pituitary adenomas in children and adolescents. Clinical Presentation, diagnosis and therapeutic strategies. The Endocrinologist 2000; 10: 314-320.
3. Mindermann T, Wilson CB. Pediatric pituitary adenomas. Neurosurgery 1995; 36: 259-269.
4. Abe T, Tara LA, Ludecke DK. Growth hormone-secreting pituitary adenomas in childhood and adolescence: features and results of transnasal surgery. Neurosurgery 1999; 45:1-10.
5. Ludecke DK, Herrmann HD, Schulte FJ. Special problems with neurosurgical treatment of hormone-secreting pituitary adenomas in children. Prog Exp Tumor Res 1987; 30: 362-370.
6. Gold EB. Epidemiology of pituitary adenomas. Epidemiol Rev 1981; 3: 163-183.
7. Haddad SF, VanGilder JC, Menezes AH. Pediatric pituitary tumors. Neurosurgery 1991; 29: 509-514.
8. Lafferty AR, Chrousos GP. Pituitary tumors in children and adolescents. J Clin Endocrinol Metab 1999; 84: 4317-4323.
9. Partington MD, Dudley HD, Laws ER, Scheithauer BW. Pituitary adenomas in childhood and adolescence. Results of transsphenoidal surgery. J Neurosurg 1994; 80: 209-216.
10. Ezzat S. The role of hormones, growth factors and their receptors in pituitary tumorigenesis. Brain Pathol 2001; 11: 356-370.
11. Melmed S. Pituitary function and neoplasia. In Jameson L, ed. Principles of Molecular Medicine Textbook. Totowa; NJ; Humana Press, 1998; 443-449.
12. Shimon I, Melmed S. Pituitary tumor pathogenesis. J Clin Endocrinol Metab 1997; 82: 1675-1681.
13. Bertherat J, Chanson P, Montminy M. The cyclic adenosine 3′,5′-monophosphate responsive factor CREB is constitutively activated in human somatotroph adenomas. Mol Endocrinol 1995; 9: 777-783.
14. Wilson CB. Role of surgery in the management of pituitary tumors. Neurosurg Clin North Am 1990; 1: 139-159.
15. Farrell WE, Simpson DJ, Bicknell JE et al. Chromosome 9p deletions in invasive and non-invasive nonfunctional pituitary adenomas: The deleted region involves markers outside of the MTS1 and MTS2 genes. Cancer Res 1997; 57: 2703-2709.
16. Prezant T, Levine J, Melmed S. Molecular characterization of the MENl tumor suppressor gene in sporadic pituitary tumors. J Clin Endocrinol Metab 1998; 83: 1388-1391.
17. Bates AS, Farrell WE, Bicknell EJ et al. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab 1997; 82: 818-824.
18. Woloschak M, Yu A, Xiao J et al. Frequent loss of the P16 (INK4a) gene product in human pituitary tumors. Cancer Res 1996; 56: 2493-2496.
19. Yang I, Park S, Ryu M et al. Characteristics of gsp-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients. Eur J Endocrinol 1996; 134: 720-726.
20. Pei L, Melmed S. Isolation and characterization of a pituitary tumor-specific transforming gene. Mol Endocrinol 1997; 11: 433-441.
21. Zhang X, Horwitz GA, Prezant TR et al. Structure, expression and function of human pituitary tumor transforming gene (PTTG). Mol Endocrinol 1999; 13: 156-166.
22. Zimering MB, Katsumata N, Sato Y et al. Increased FGF in plasma from multiple endocrine neoplasia type I. Relation of pituitary tumor. J Clin Endocrinol Metab 1993; 76: 1182-1187.
23. Shimon I, Hinton DR, Weiss MH et al. Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: Marker of tumor invasiveness. Clin Endocrinol 1998; 48: 23-29.
24. Dissaneevate P, Warne GL. Hyperprolactinaemia and pituitary adenomas in adolescence. J Pediatr Endocrinol Metab 1998; 11: 531-541.
25. Cannavo S, Venturino M, Curto L, De Menis E et al. Clinical presentation and outcome of pituitary adenomas in teenagers. Clin Endocrinol (Oxf) 2003; 58(4): 519-527.
26. Colao A, Loche S, Cappa M et al. Prolactinomas in children and adolescents. Clinical presentation and long term follow up. J Clin Endocrinol Metab 1998; 82: 2777-2780.
27. Colao A, Di Somma C, Loche S et al. Prolactinomas in children and adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol 2000; 52: 319-328.
28. Blackwell RE, Younger BJ. Long-term medical therapy and follow up of pediatric adolescent patients with prolactin-secreting macroadenomas. Fertil Steril 1986; 45: 713-716.
29. Colao A, Annunziato L, Lombardi G. Treatment of prolactinomas. Ann Med 1998; 30: 452-459.
30. Laws ER, Scheithauer BW, Groover RV. Pituitary adenomas in childhood and adolescence. Prog Exp Tumor Res 1987; 30: 359-361.
31. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998; 19: 647-672.
32. Magiakou MA, Mastorakos G, Oldfield Eh et al. Cushing's syndrome in children and adolescents. Presentation, diagnosis and therapy. N Engl J Med 1994; 331: 629-636.
33. Weber A, Trainer PJ, Grossman AB et al. Investigation, management and therapeutic outcome in 12 cases of childhood and adolescent Cushing's syndrome. Clin Endocrinol 1995; 43: 19-28.
34. Styne DM, Grumbach MM, Kaplan SA, Wilson CB, Conte FA. Treatment of Cushing's disease in childhood and adolescence by transphenoidal microadenomectomy. N Engl J Med 1984; 310: 889-893.
35. Lebrethon MC, Grossman AB, Afshar F, Plowman PN, Besser GM, Savage MO. Linear growth and final height after treatment for Cushing's disease in childhood. J Clin Endocrinol Metab 2000; 85: 3262-3265.
36. Colao A, Lombardi G. GH and PRL excess. Lancet 1998; 352: 1455-1461.
37. Eugster EA, Pescovitz OH. Gigantism. J Clin Endocrinol Metab 1999; 84: 4379-4389.
38. Sotos JF. Overgrowth, section II. Clin Pediatr 1996; 35: 579-590.
39. Alvi NS, Kirk JM. Pituitary gigantism causing diabetic ketoacidosis. J Pediatr Endocrinol Metab 1999; 12: 907-909.
40. Giustina A, Barkan A, Casanueva FF et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000; 85: 526-529.
41. Moran A, Pescovitz OH. Long-term treatment of gigantism with combination octreotide and bromocriptine in a child with McCune-Albright syndrome. Endocr J 1994; 2: 111-113.
42. Beck-Peccoz P, Bruckner-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin secreting pituitary tumors. Endocr Rev 1996; 17: 610-638.
43. Freda PU, Wardlaw SL. Diagnosis and treatment of pituitary tumors. J Clin Endocrinol Metab 1999; 84: 3859-3866.
44. Katnelson L, Alexander JM, Klibanski A. Clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 1993; 76: 1089-1094.
45. Fukuda T, Yokoyama N, Tamai M et al. Thyrotropin secreting pituitary adenoma effectively treated with octreotide. Intern Med 1998; 37: 1027-1030.
46. Colao A, Ferone D, Lastoria S et al. Hormone levels and tumor size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning adenomas: predictive value of pituitary scintigraphy with 1231-Methoxybenzamide. Clin Endocrinol 2000; 52: 437-445.